Literature DB >> 29651876

Novel hits for acetylcholinesterase inhibition derived by docking-based screening on ZINC database.

Irini Doytchinova1,2, Mariyana Atanasova1, Iva Valkova1,2, Georgi Stavrakov1,3, Irena Philipova3, Zvetanka Zhivkova1, Dimitrina Zheleva-Dimitrova1, Spiro Konstantinov1, Ivan Dimitrov1.   

Abstract

The inhibition of the enzyme acetylcholinesterase (AChE) increases the levels of the neurotransmitter acetylcholine and symptomatically improves the affected cognitive function. In the present study, we searched for novel AChE inhibitors by docking-based virtual screening of the standard lead-like set of ZINC database containing more than 6 million small molecules using GOLD software. The top 10 best-scored hits were tested in vitro for AChE affinity, neurotoxicity, GIT and BBB permeability. The main pharmacokinetic parameters like volume of distribution, free fraction in plasma, total clearance, and half-life were predicted by previously derived models. Nine of the compounds bind to the enzyme with affinities from 0.517 to 0.735 µM, eight of them are non-toxic. All hits permeate GIT and BBB and bind extensively to plasma proteins. Most of them are low-clearance compounds. In total, seven of the 10 hits are promising for further lead optimisation. These are structures with ZINC IDs: 00220177, 44455618, 66142300, 71804814, 72065926, 96007907, and 97159977.

Entities:  

Keywords:  ITC; Neuro 2A; PAMPA; Virtual screening; molecular docking

Mesh:

Substances:

Year:  2018        PMID: 29651876      PMCID: PMC6010092          DOI: 10.1080/14756366.2018.1458031

Source DB:  PubMed          Journal:  J Enzyme Inhib Med Chem        ISSN: 1475-6366            Impact factor:   5.051


  46 in total

Review 1.  On neurodegenerative diseases, models, and treatment strategies: lessons learned and lessons forgotten a generation following the cholinergic hypothesis.

Authors:  R T Bartus
Journal:  Exp Neurol       Date:  2000-06       Impact factor: 5.330

Review 2.  Multi-target design strategies in the context of Alzheimer's disease: acetylcholinesterase inhibition and NMDA receptor antagonism as the driving forces.

Authors:  Michela Rosini; Elena Simoni; Anna Minarini; Carlo Melchiorre
Journal:  Neurochem Res       Date:  2014-02-04       Impact factor: 3.996

3.  Use of ligand-based pharmacophore modeling and docking approach to find novel acetylcholinesterase inhibitors for treating Alzheimer's.

Authors:  Jaspreet Kaur Dhanjal; Sudhanshu Sharma; Abhinav Grover; Asmita Das
Journal:  Biomed Pharmacother       Date:  2015-03-05       Impact factor: 6.529

4.  Docking-based design and synthesis of galantamine-camphane hybrids as inhibitors of acetylcholinesterase.

Authors:  Georgi Stavrakov; Irena Philipova; Dimitrina Zheleva-Dimitrova; Iva Valkova; Evdokiya Salamanova; Spiro Konstantinov; Irini Doytchinova
Journal:  Chem Biol Drug Des       Date:  2017-05-12       Impact factor: 2.817

5.  Synthesis, biological evaluation, and molecular modeling of donepezil and N-[(5-(benzyloxy)-1-methyl-1H-indol-2-yl)methyl]-N-methylprop-2-yn-1-amine hybrids as new multipotent cholinesterase/monoamine oxidase inhibitors for the treatment of Alzheimer's disease.

Authors:  Irene Bolea; Jordi Juárez-Jiménez; Cristóbal de Los Ríos; Mourad Chioua; Ramón Pouplana; F Javier Luque; Mercedes Unzeta; José Marco-Contelles; Abdelouahid Samadi
Journal:  J Med Chem       Date:  2011-11-15       Impact factor: 7.446

6.  Donepezil + propargylamine + 8-hydroxyquinoline hybrids as new multifunctional metal-chelators, ChE and MAO inhibitors for the potential treatment of Alzheimer's disease.

Authors:  Li Wang; Gerard Esteban; Masaki Ojima; Oscar M Bautista-Aguilera; Tsutomu Inokuchi; Ignacio Moraleda; Isabel Iriepa; Abdelouahid Samadi; Moussa B H Youdim; Alejandro Romero; Elena Soriano; Raquel Herrero; Ana Patricia Fernández Fernández; José Marco-Contelles; Mercedes Unzeta
Journal:  Eur J Med Chem       Date:  2014-04-29       Impact factor: 6.514

Review 7.  Clinical pharmacokinetics of galantamine.

Authors:  Martin R Farlow
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

8.  Galantamine derivatives with indole moiety: Docking, design, synthesis and acetylcholinesterase inhibitory activity.

Authors:  Mariyana Atanasova; Georgi Stavrakov; Irena Philipova; Dimitrina Zheleva; Nikola Yordanov; Irini Doytchinova
Journal:  Bioorg Med Chem       Date:  2015-07-29       Impact factor: 3.641

Review 9.  Dual inhibitors of β-amyloid aggregation and acetylcholinesterase as multi-target anti-Alzheimer drug candidates.

Authors:  Elisabet Viayna; Raimon Sabate; Diego Muñoz-Torrero
Journal:  Curr Top Med Chem       Date:  2013       Impact factor: 3.295

10.  Virtual screening and structure-based discovery of indole acylguanidines as potent β-secretase (BACE1) inhibitors.

Authors:  Yiquan Zou; Li Li; Wuyan Chen; Tiantian Chen; Lanping Ma; Xin Wang; Bing Xiong; Yechun Xu; Jingkang Shen
Journal:  Molecules       Date:  2013-05-16       Impact factor: 4.411

View more
  9 in total

1.  Discovery of new multifunctional selective acetylcholinesterase inhibitors: structure-based virtual screening and biological evaluation.

Authors:  Cheng-Shi Jiang; Yong-Xi Ge; Zhi-Qiang Cheng; Jia-Li Song; Yin-Yin Wang; Kongkai Zhu; Hua Zhang
Journal:  J Comput Aided Mol Des       Date:  2019-04-15       Impact factor: 3.686

2.  Virtual Screening and Hit Selection of Natural Compounds as Acetylcholinesterase Inhibitors.

Authors:  Mariyana Atanasova; Ivan Dimitrov; Stefan Ivanov; Borislav Georgiev; Strahil Berkov; Dimitrina Zheleva-Dimitrova; Irini Doytchinova
Journal:  Molecules       Date:  2022-05-13       Impact factor: 4.927

3.  Computational Identification of Potential Anti-Inflammatory Natural Compounds Targeting the p38 Mitogen-Activated Protein Kinase (MAPK): Implications for COVID-19-Induced Cytokine Storm.

Authors:  Seth O Asiedu; Samuel K Kwofie; Emmanuel Broni; Michael D Wilson
Journal:  Biomolecules       Date:  2021-04-29

4.  Cheminformatics-Based Identification of Potential Novel Anti-SARS-CoV-2 Natural Compounds of African Origin.

Authors:  Samuel K Kwofie; Emmanuel Broni; Seth O Asiedu; Gabriel B Kwarko; Bismark Dankwa; Kweku S Enninful; Elvis K Tiburu; Michael D Wilson
Journal:  Molecules       Date:  2021-01-14       Impact factor: 4.411

5.  Drug Design-Past, Present, Future.

Authors:  Irini Doytchinova
Journal:  Molecules       Date:  2022-02-23       Impact factor: 4.411

6.  Novel Hits for N-Myristoyltransferase Inhibition Discovered by Docking-Based Screening.

Authors:  Danislav S Spassov; Mariyana Atanasova; Irini Doytchinova
Journal:  Molecules       Date:  2022-08-26       Impact factor: 4.927

7.  Acteoside and ursolic acid synergistically protects H2O2-induced neurotrosis by regulation of AKT/mTOR signalling: from network pharmacology to experimental validation.

Authors:  Yan-Jie Qu; Min-Rui Ding; Chao Gu; Li-Min Zhang; Rong-Rong Zhen; Jin-Fang Chen; Bing Hu; Hong-Mei An
Journal:  Pharm Biol       Date:  2022-12       Impact factor: 3.889

8.  Discovery of new acetylcholinesterase inhibitors for Alzheimer's disease: virtual screening and in vitro characterisation.

Authors:  Benoit David; Pascal Schneider; Philipp Schäfer; Jörg Pietruszka; Holger Gohlke
Journal:  J Enzyme Inhib Med Chem       Date:  2021-12       Impact factor: 5.051

9.  Computational Study on Potential Novel Anti-Ebola Virus Protein VP35 Natural Compounds.

Authors:  Louis K S Darko; Emmanuel Broni; Dominic S Y Amuzu; Michael D Wilson; Christian S Parry; Samuel K Kwofie
Journal:  Biomedicines       Date:  2021-11-30
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.